Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Photocure ASA ( (PHCUF) ) has provided an announcement.
Photocure ASA presented a study at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, highlighting the effectiveness of Blue Light Cystoscopy (BLC) with Cysview in detecting tumors in non-muscle-invasive bladder cancer (NMIBC) patients. The study, involving 2,854 patients, found that BLC revealed malignant lesions undetected by standard white light cystoscopy in 7% of cases, leading to a 9.3% rate of tumor upgrading or upstaging. This advancement in detection is expected to enhance patient management, potentially altering treatment protocols and supporting further precision diagnostic studies.
More about Photocure ASA
Photocure ASA, known as The Bladder Cancer Company, focuses on providing innovative solutions for bladder cancer treatment. The company leverages its unique technology that makes cancer cells glow bright pink, enhancing tumor detection and improving patient outcomes. Photocure is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange.
YTD Price Performance: -2.63%
Average Trading Volume: 810
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $140.4M
For a thorough assessment of PHCUF stock, go to TipRanks’ Stock Analysis page.
